硫普罗宁联合促肝细胞生长素对慢性乙型肝炎患者炎症反应及生化指标的影响  

Effect of tiopronin combined with hepatocyte growth promoting factor on inflammatory response and biochemical indicators in patients with chronic

作　　者：刘桢 LIU Zhen(Department of Infection,Ruijin People's Hospital,Ruijin,Jiangxi,342500,China)

机构地区：[1]瑞金市人民医院感染科,江西瑞金342500

出　　处：《当代医学》2023年第22期37-40,共4页Contemporary Medicine

摘　　要：目的探讨硫普罗宁联合促肝细胞生长素对慢性乙型肝炎(CHB)患者炎症反应及生化指标的影响。方法选取2019年6月至2021年6月本院收治的74例CHB患者作为研究对象,按随机数字表法分为对照组与研究组,各37例。对照组给予促肝细胞生长素治疗,研究组采用硫普罗宁联合促肝细胞生长素治疗。比较两组炎症反应指标[WBC、C反应蛋白(CRP)、白细胞介素(IL)-10、IL-12]、生化指标[丙氨酸氨基转移酶(ALT)、总胆红素(TBil)、天冬氨酸氨基转移酶(AST)、透明质酸梅(HA)、层粘连蛋白(LN)、Ⅲ型胶原(PCⅢ)]及不良反应。结果治疗前,两组WBC、CRP、IL-10、IL-12水平比较差异无统计学意义;治疗后,两组WBC、CRP、IL-10、IL-12均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组ALT、TBil、AST、HA、LN、PCⅢ水平比较差异无统计学意义;治疗后,两组ALT、TBil、AST、HA、LN、PCⅢ均水平低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论硫普罗宁联合促肝细胞生长素能有效减轻CHB患者机体炎症反应,抑制肝纤维化,改善肝功能,安全性高,值得临床推广应用。Objective To investigate the effect of tiopronin combined with hepatocyte growth promoting factor on inflammatory response and biochemical indicators in patients with chronic hepatitis B(CHB).Methods 74 CHB patients admitted to our hospital from June 2019 to June 2021 were selected as the study subjects,they were divided into the control group and the study group according to the random number table method,with 37 cases in each group.The control group was treated with hepatocyte growth promoting factor,while the study group was treated with tiopronin combined with hepatocyte growth promoting factor.The inflammatory reaction indexes(WBC,C-reactive protein[CRP],interleukin[IL]-10,IL-12),biochemical indexes(alanine aminotransferase[ALT],total bilirubin[TBil],aspartate transaminase[AST],hyaluronic acid plum[HA],laminin[LN],typeⅢcollagen[PCⅢ])and adverse reactions were compared between the two groups.Results Before treatment,there was no statistically signifi-cant difference in the levels of WBC,CRP,IL-10,and IL-12 between the two groups;after treatment,the levels of WBC,CRP,IL-10,and IL-12 of the two groups were lower than before treatment,and the study group was lower than the control group,the differences were statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the levels of ALT,TBil,AST,HA,LN,and PCⅢbetween the two groups;after treatment,the levels of ALT,TBil,AST,HA,LN,and PCⅢof the two groups were lower than before treatment,and the study group was lower than the control group,the differences were statistically significant(P<0.05).There was no statistically significant difference in the inci-dence of adverse reactions between the two groups.Conclusion Tiopronin combined with hepatocyte growth promoting factor can effectively re-duce the inflammatory reaction of CHB patients,inhibit liver fibrosis,improve liver function,with high safety,and is worthy of clinical promotion and application.

关 键 词：慢性乙型肝炎 硫普罗宁 促肝细胞生长素 炎症反应 生化指标 

分 类 号：R512.62[医药卫生—内科学]